High lovastatin doses combined with hypercholesterolemic diet induce hepatic damage and are lethal to the CD-1 mouse

被引:5
作者
Asenjo-Barrón, JC
Cárdenas-Vázquez, R
Martínez, F
Juárez-Oropeza, MA
Díaz-Zagoya, JC
机构
[1] Natl Autonomous Univ Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico
[2] Natl Autonomous Univ Mexico, Fac Ciencias, Dept Biol, Mexico City 04510, DF, Mexico
[3] UJAT, Div Acad Ciencias Salud, Mexico City 04510, DF, Mexico
关键词
lovastatin; lethality; hypercholesterolemic diet; female CD-1 mouse; male CD-1 mouse;
D O I
10.1016/S0024-3205(99)00162-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The addition of 1% lovastatin (LVT) to hypercholesterolemic diets [1% cholesterol or 1% cholesterol plus 0.1% sodium deoxycholate (HD)] induced hepatic damage and was lethal to CD-1 mice in the first days of treatment; the females were more resistant than males. LVT or HD administered alone was harmless to male or female mice. After a 3-day treatment all groups that received LVT (1%, 0.1% or 0.05%) plus HD showed a higher percentage of liver weight, with respect to whole body weight. Cholesterol serum levels increased in males with HD, but remained low in female mice. In the liver, total lipids and cholesterol levels increased in male mice with HD, but cholesterol remained unchanged in females. The addition of LVT to HD prevented the increase of serum and liver cholesterol levels in male mice. These results allow us to propose the CD-1 male-mouse as a model to evaluate the toxicity of LVT or other vastatins.
引用
收藏
页码:2155 / 2161
页数:7
相关论文
共 13 条
[1]   EVIDENCE OF PLASMA COQ10-LOWERING EFFECT BY HMG-COA REDUCTASE INHIBITORS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
GHIRLANDA, G ;
ORADEI, A ;
MANTO, A ;
LIPPA, S ;
UCCIOLI, L ;
CAPUTO, S ;
GRECO, AV ;
LITTARRU, GP .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (03) :226-229
[2]   BIOCHEMICAL-CHANGES AND MORPHOLOGICAL ALTERATIONS OF THE LIVER IN GUINEA-PIGS AFTER ADMINISTRATION OF SIMVASTATIN (HMG COA REDUCTASE-INHIBITOR) [J].
HORSMANS, Y ;
DESAGER, JP ;
HARVENGT, C .
PHARMACOLOGY & TOXICOLOGY, 1990, 67 (04) :336-339
[3]   Increased cellular triglyceride levels in human monocytic and rat smooth muscle cells after lovastatin [J].
Hrboticky, N ;
Becker, A ;
Kruse, HJ ;
Weber, PC .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1997, 1349 (03) :211-221
[4]   Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women [J].
Korhonen, T ;
Savolainen, MJ ;
Koistinen, MJ ;
Ikaheimo, M ;
Linnaluoto, MK ;
Kervinen, K ;
Kesaniemi, YA .
ATHEROSCLEROSIS, 1996, 127 (02) :213-220
[5]  
KORNBRUST DJ, 1989, J PHARMACOL EXP THER, V248, P498
[6]  
LEVY RI, 1993, CIRCULATION, V87, P45
[7]  
MACDONALD JS, 1988, AM J CARDIOL, V62, P16
[8]   Perimenopausal obesity [J].
Milewicz, A ;
Bidzinska, B ;
Sidorowicz, A .
GYNECOLOGICAL ENDOCRINOLOGY, 1996, 10 (04) :285-291
[9]   EXPERIMENTAL SIMVASTATIN-INDUCED MYOPATHY IN RABBITS [J].
NAKAHARA, K ;
KURIYAMA, M ;
YOSHIDOME, H ;
NAGATA, K ;
NAGADO, T ;
NAKAGAWA, M ;
ARIMURA, K ;
HIGUCHI, I ;
OSAME, M .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1992, 113 (01) :114-117
[10]   BIOCHEMICAL-CHANGES AND MORPHOLOGICAL ALTERATIONS OF LIVER AND KIDNEY IN HAMSTERS AFTER ADMINISTRATION OF THE HMG-COENZYME-A REDUCTASE INHIBITOR, SIMVASTATIN - PREVENTION AND REVERSIBILITY BY MEVALONATE [J].
OMS, P ;
ASSIE, N ;
BRUNIQUEL, F ;
DEGRYSE, AD ;
VANHAVERBEKE, G ;
DELHON, A .
PHARMACOLOGY & TOXICOLOGY, 1995, 77 (06) :391-396